Institutional Biosafety Committee
Meeting Minutes

Date: 03/30/2026 Start time: 3:00pm (ET) End time: 5:00pm (ET)

Advarra IBC meetings are closed to the public to protect confidential and proprietary information as outlined in the Advarra IBC standard operating procedures.

Chair: Warren Rummage

Voting Members Present: Dan Eisenman (Committee Member), Scott Swindle (Committee Member), Darlene Ward (Committee Member), Nichole Tower (Committee Member), Alain Houmeidan (Committee Member), Jackie Lomeli (Committee Member), Paul Gulig (Committee Member), Beata Clapp (Committee Member), No Community Members were present for this review. The Community Member that was assigned to this review was unable to attend the meeting. The committee voted unanimously in favor to conduct the review without a Community Member in attendance.

Other Persons Present: [redacted]

Conflict of Interest: The IBC Chair queried the IBC to identify any potential conflicts of interest and requested that any potential conflicts of interest be disclosed to the IBC. The IBC Chair then reminded the IBC that if any potential conflicts of interest were identified as the meeting progressed, disclosure would need to occur at that time. Identified potential conflict of interest: ☐ Yes ☒ No

Study Summary Information for Minutes			
Protocol #	[redacted]	**IBC Study Submission ID #**	PROTO202500115
Study Title	A Randomized, Controlled, Partially Masked, Phase 3b Study to Assess the Injection Burden, Efficacy, Safety, and Long-Term Preservation of Visual Acuity of [redacted] in a Real-World Context in Subjects with Neovascular Age-Related Macular Degeneration (nAMD)		
Agent	Adeno-Associated Virus (AAV)		
Agent Characteristics	Replication deficient vector; Risk Group 1		
rDNA Category	III-C-1		

Description of Recombinant Nucleic Acid Sources	• Gene encoding [redacted]
Description of Genetically Modified Microbes or Vectors	• Replication-deficient Adeno-associated virus (AAV)
Description of Transgene Expression	• [redacted]

Risk Assessment of Procedures	• Preparation of Dose
	  ○ Sharps Safety
	  ○ Standard Precautions
	• Administered Injection into the Eye
	  ○ Sharps Safety
	  ○ Standard Precautions
	• Dispose of all materials as biohazardous waste

Site Information

Site Name	Monmouth Retina Consultants - Little Silver, NJ	**IBC Site Submission ID #**	SAF202600079
PI Name	Konstantin Astafurov		
Site Biosafety Level	BSL2		
Staff Training Verified by PI Signed SOP	☒ Yes ☐ No		

Motions, Votes, and Committee's Decision

Motion: Approve		
Conditions: N/A		
Motion	**First:** [redacted]	**Second:** [redacted]

Votes	For: 9	Against: 0	Recused: 0	Absent: 0	Abstained: 0

Chair Signature
Approved by Chair:
Name: Warren Rummage
Date: 2026/03/31